2023
AACR, April 17. Poster.
“KSQ-4279, a first-in-class USP1 inhibitor, shows strong combination activity with multiple PARP inhibitors in BRCA mutant cancers”
AACR, April 17. Poster.
“KSQ-4279-mediated USP1 inhibition induces replication-associated DNA gaps that contribute to cell death”
2022
SITC. Nov. 11. Poster.
“ExPRESS™: An accelerated process for the manufacture of KSQ-001, a CRISPR/Cas9-edited eTIL® product”
SITC. Nov. 11. Poster.
“Manufacture of KSQ-001, a CRISPR/Cas9-engineered TIL (eTIL®) therapy, for the treatment of Head and Neck Squamous Cell Carcinoma”
EORTC-NIC-AACR. Oct. 26. Poster.
“KSQ-4279, a first-in-class USP1 inhibitor shows strong combination activity in BRCA mutant cancers with intrinsic or acquired resistance to PARP inhibitors”
AACR. April 10. Presentation.
“KSQ-4279: A first-in-class USP1 inhibitor for the treatment of cancers with homologous recombination deficiency”
2021
SITC. Nov 13. Poster.
“KSQ-004: Unbiased Pair-wise Discovery of SOCS1 and Regnase-1 as the Top CRISPR/Cas9 Dual-edit Combination Enhancing in vivo TIL Potency Against Solid Tumors”
SITC. Nov 13. Poster.
“Development of KSQ-001, an Engineered TIL (eTIL®) Therapy for Solid Tumors through CRISPR/Cas9-mediated Inactivation of SOCS1”
AACR. April 10. Poster.
“Functional genomic characterization of the USP1 inhibitor KSQ-4279 reveals a distinct mechanism of action and resistance profile relative to other DDR targeting drugs”
2020
EORTC. October 24.
Plenary Slide Deck: “USP1 inhibitors show robust combination activity and a distinct resistance profile from PARP inhibitors”
EORTC. October 24. Poster.
“Development of KSQ-4279 as a First-in-Class USP1 Inhibitor for the Treatment of BRCA-Deficient Cancers”
AACR. June 22. Poster.
“KSQ-001: A CRISPR/Cas9-Engineered Tumor Infiltrating Lymphocyte (eTIL®) Therapy for Solid Tumors”
ASGCT. May 12. Poster.
“Systematic identification of potent guide RNAs with minimal off-target activity for the CRISPR/Cas9 engineering of KSQ-001, an engineered Tumor Infiltrating Lymphocyte (eTIL®)”
Keystone Symposia: Engineering the Genome. Feb. 9.
“Genome-scale in vivo CRISPR/Cas9 T cell screen unveils targets enabling rational design of engineered Tumor Infiltrating Lymphocyte (eTIL®) therapies for solid tumors”
2019
SITC. Nov. 9.
“An Immune-CRISPRomics platform enabling genome-scale and pair-wise combination in vivo T-cell function screens enables comprehensive identification of novel therapeutic targets”
EORTC. Oct. 29.
Comprehensive Identification of Novel Therapeutic Targets for Treatment of PD-1 Resistance Solid Tumors via a Genome-Scale CRISPR/Cas9 in vivo T-cell Screen”
2016
CRISPR Screens Provide a Comprehensive Assessment of Cancer Vulnerabilities but Generate False-Positive Hits for Highly Amplified Genomic Regions.
Munoz DM, Cassiani PJ, Li L, Billy E, Korn JM, Jones MD, Golji J, Ruddy DA, Yu K, McAllister G, DeWeck A, Abramowski D, Wan J, Shirley MD, Neshat SY, Rakiec D, de Beaumont R, Weber O, Kauffman A, McDonald 3rd ER, Keen N, Hofmann F, Sellers WR, Schmelzle T, Stegmeier F, Schlabach MR. Cancer Discov. 2016 Aug;6(8):900-13
2014
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Cowley GS, Weir BA, Vazquez F, Tamayo P, Scott JA, Rusin S, East-Seletsky A, Ali LD, Gerath WF, Pantel SE, Lizotte PH, Jiang G, Hsiao J, Tsherniak A, Dwinell E, Aoyama S, Okamoto M, Harrington W, Gelfand E, Green TM, Tomko MJ, Gopal S, Wong TC, Li H, Howell S, Stransky N, Liefeld T, Jang D, Bistline J, Hill Meyers B, Armstrong SA, Anderson KC, Stegmaier K, Reich M, Pellman D, Boehm JS, Mesirov JP, Golub TR, Root DE, Hahn WC. Sci Data. 2014 Sep 30;1:140035.
Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation.
Gilbert LA, Horlbeck MA, Adamson B, Villalta JE, Chen Y, Whitehead EH, Guimaraes C, Panning B, Ploegh HL, Bassik MC, Qi LS, Kampmann M, Weissman JS. Cell. 2014 Oct 23;159(3):647-61.
Genetic screens in human cells using the CRISPR-Cas9 system.
Wang T, Wei JJ, Sabatini DM, Lander ES. Science. 2014 Jan 3;343(6166):80-4.
